Curated News
By: NewsRamp Editorial Staff
June 02, 2026

Quantum BioPharma's Lucid-MS Takes Center Stage on BioMedWire Podcast

Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Quantum BioPharma's Lucid-MS targets an unmet need in MS mobility, offering a potential first-mover advantage in nerve repair.
  • Lucid-MS reverses myelin degradation in preclinical models; Phase 2 trial will evaluate it in MS patients after Phase 1 safety.
  • Lucid-MS aims to restore mobility for MS patients, improving quality of life by addressing the root cause of nerve damage.
  • Quantum also sells unbuzzd, an alcohol metabolism product, and earns royalties from its sales alongside developing Lucid-MS.

Impact - Why it Matters

This news matters because Quantum BioPharma is tackling a critical unmet need in multiple sclerosis: mobility loss from nerve damage, which current treatments don't fully address. If Lucid-MS succeeds in Phase 2 trials, it could offer a new therapeutic option for millions of MS patients worldwide. Additionally, their commercial product unbuzzd(TM) provides a novel solution for alcohol metabolism, potentially reducing alcohol-related harm. For investors, the company's pipeline and royalty stream from unbuzzd(TM) sales represent multiple value drivers.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies, was highlighted on the latest episode of the BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, which targets mobility loss associated with multiple sclerosis by addressing nerve damage—an area Durkacz believes remains unmet by current treatments. The company also showcased its commercial alcohol metabolism product, unbuzzd(TM), designed to accelerate blood alcohol metabolism and currently available in the U.S. market. Looking ahead, Quantum BioPharma is preparing for its upcoming Phase 2 clinical trial for Lucid-MS, the first study to evaluate the drug candidate in multiple sclerosis patients after Phase 1 testing in healthy volunteers.

Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS, a patented new chemical entity that has shown promise in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis. Additionally, Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd and receives royalty payments of 7% of sales from unbuzzd(TM) until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains full rights to develop similar products for pharmaceutical and medical uses.

The BioMedWire Podcast episode provides a comprehensive look at Quantum BioPharma’s strategy and pipeline, emphasizing the potential of Lucid-MS to address a significant unmet need in multiple sclerosis care. For more details, the full press release is available at https://ibn.fm/HURxt. As the company advances its clinical programs, investors and patients alike are watching closely for developments that could impact the treatment landscape for neurodegenerative diseases.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Takes Center Stage on BioMedWire Podcast

blockchain registration record for this content.